EXTH-74. IND-ENABLING CHARACTERIZATION OF DUAL DRD2- AND ClpP-TARGETING AGENT ONC206 AS THE NEXT IMIPRIDONE FOR CLINICAL NEURO-ONCOLOGY

ONC201 is the first bitopic antagonist of dopamine receptor D2 (DRD2) and allosteric mitochondrial protease ClpP agonist, that is well tolerated and induces durable tumor regressions in H3 K27M-mutant glioma patients. ONC206, a derivative of ONC201, is also a bitopic DRD2 antagonist that exhibits en...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neuro Oncol
Autors principals: Prabhu, Varun, Morrow, Sara, Kawakibi, Abed Rahman, Jitkova, Yulia, Jung, Jinkyu, Madhukar, Neel, Garnett, Mathew, McDermott, Ultan, Benes, Cyril, Wechsler-Reya, Robert, Elemento, Olivier, DeMorrow, Sharon, Schimmer, Aaron, Stogniew, Martin, Theeler, Brett, Gilbert, Mark, Allen, Joshua
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2020
Matèries:
Preclinical Experimental Therapeutics
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7650984/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.428
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars